Danish pharmaceutical company Novo Nordisk has launched its popular weight-loss drug Wegovy in China, a market with over 180 million people living with obesity.
The launch follows regulatory approval granted in June, targeting patients paying out-of-pocket as the drug will not be covered by China’s national healthcare insurance. Novo’s move intensifies competition with Eli Lilly, which gained approval for its obesity drug in July but has yet to launch it.
With the global weight-loss market projected to surpass $150 billion by the next decade, both companies are ramping up production to meet growing demand. Wegovy’s success in the U.S. and 15 other countries has significantly boosted Novo’s market value, currently at $449 billion.
CNN, BBC NEWS, ARY NEWS, GEO NEWS
